Beneficial effects of Bifidobacterium longum subsp. longum BB536 on human health: Modulation of gut microbiome as the principal action

Wong, Chyn Boon; Odamaki, Toshitaka; Xiao, Jin‐zhong

doi:10.1016/j.jff.2019.02.002

Cited by 90 publications

(57 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this regard, our results showed a negative correlation between the β-GA, pH and the bacterial colonization; therefore, the overactivity of the β-GA enzyme and basicity of pH contribute to a lesser bacterial colonization in the luminal zone ( p < 0.05), while in the tissue-adherent zone, the bacterial colonization was only negatively correlated with the overactivity of β-GA in the caecum, colon, and feces. Our results agree with the anticarcinogenic mechanisms associated to the administration of BF [9,10]. However, this is the first report to demonstrate that LYC- and Metformin-treatments decrease colonic fecal pH and β-GA values in mouse colon carcinogenesis, thus confirming their application as therapeutic intestinal targets in the AOM-DSS model.…”

Section: Discussionsupporting

confidence: 89%

“…The anticarcinogenic mechanisms associated with the administration of B. longum include: control of cell growth and differentiation, fermentation of non-digestible carbohydrates to produce short-chain fatty acids, modulation of the gut microbiome, reduction of pH caused by the excessive presence of bile acids in feces, inhibition of colon carcinoma cell proliferation as well as induction of apoptosis in colon carcinoma cells [9,10]. A daily intake of at least 1 × 10 7 viable cells has been suggested as the minimum intake to provide a protective effect.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oral Administration of Microencapsulated B. Longum BAA-999 and Lycopene Modulates IGF-1/IGF-1R/IGFBP3 Protein Expressions in a Colorectal Murine Model

Valadez-Bustos

Escamilla‐Silva

García-Vázquez

et al. 2019

IJMS

View full text Add to dashboard Cite

The Insulin-like growth factor-I/Insulin-like growth factor-I receptor (IGF-1/IGF-1R) system is a major determinant in colorectal cancer (CRC) pathogenesis. Probiotics (Bifidobacterium longum, BF) and lycopene (LYC) have been individually researched for their beneficial effects in the prevention of CRC. However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated. BF was microencapsulated by the spray drying technique, with high viability, and daily gavaged with LYC for 16 weeks to CD-1 mice in an AOM-DSS model. The results indicated that BF- and BF + LYC-treated groups had significantly lower inflammation grade, tumor incidence (13–38%) and adenocarcinoma (13–14%) incidence compared to the AOM + DSS group (80%), whereas LYC treatment only protected against inflammation grade and incidence. Caecal, colonic and fecal pH and β-glucuronidase (β-GA) values were significantly normalized by BF and LYC. Similarly, BF and BF + LYC treatments significantly reduced both the positive rate and expression grade of IGF-1 and IGF-1R proteins and normalized Insulin-like growth factor-binding protein-3 (IGFBP3) expression. Based on intestinal parameters related to the specific colon carcinogenesis in an AOM-DSS-induced model, LYC and microencapsulated BF supplementation resulted in a significant chemopreventive potential through the modulation of IGF-1/IGF-1R system.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Oral Administration of Microencapsulated B. Longum BAA-999 and Lycopene Modulates IGF-1/IGF-1R/IGFBP3 Protein Expressions in a Colorectal Murine Model

Valadez-Bustos

Escamilla‐Silva

García-Vázquez

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…From an applied perspective, our findings have implications for the targeted use of arabinoxylan to modulate the gut microbiota for improved health. Probiotic treatments with B. longum strains have been shown to be health-promoting in a variety of contexts [65], including gastrointestinal [66,67], immunological (e.g., anti-allergy and anti-inflammatory [68,69]), and psychological (e.g., depression and anxiety [70,71]) disorders. The specific enrichment of this species supports the use of arabinoxylan in synbiotic applications with B. longum.…”

Section: Discussionmentioning

confidence: 99%

Gut microbiota modulation with long-chain corn bran arabinoxylan in adults with overweight and obesity is linked to an individualized temporal increase in fecal propionate

et al. 2020

View full text Add to dashboard Cite

Background: Variability in the health effects of dietary fiber might arise from inter-individual differences in the gut microbiota's ability to ferment these substrates into beneficial metabolites. Our understanding of what drives this individuality is vastly incomplete and will require an ecological perspective as microbiomes function as complex interconnected communities. Here, we performed a parallel two-arm, exploratory randomized controlled trial in 31 adults with overweight and class-I obesity to characterize the effects of long-chain, complex arabinoxylan (n = 15) at high supplementation doses (female: 25 g/day; male: 35 g/day) on gut microbiota composition and short-chain fatty acid production as compared to microcrystalline cellulose (n = 16, non-fermentable control), and integrated the findings using an ecological framework. Results: Arabinoxylan resulted in a global shift in fecal bacterial community composition, reduced α-diversity, and the promotion of specific taxa, including operational taxonomic units related to Bifidobacterium longum, Blautia obeum, and Prevotella copri. Arabinoxylan further increased fecal propionate concentrations (p = 0.012, Friedman's test), an effect that showed two distinct groupings of temporal responses in participants. The two groups showed differences in compositional shifts of the microbiota (p ≤ 0.025, PERMANOVA), and multiple linear regression (MLR) analyses revealed that the propionate response was predictable through shifts and, to a lesser degree, baseline composition of the microbiota. Principal components (PCs) derived from community data were better predictors in

show abstract

“…Bifidobacteria are a dominant group of the gut microbiota and play an important role in promoting a favorable gut ecosystem and possess immunoregulatory effects in animals and humans ( Vuyst and Leroy, 2011 ; Hill et al, 2017 ). Some species of Bifidobacterium have been found to beneficially coexist with other members of the commensal microbiota ( Turroni et al, 2016 ; Wong et al, 2019 ) and affect the immune system ( Philippe et al, 2011 ; Tsai et al, 2012 ; Routy et al, 2018 ). This is based on the interaction of a specific bifidobacteria molecule, a microbe-associated molecular pattern (MAMP), with a pattern recognition receptor (PRR) present on the membrane of epithelial/immune cells, which mostly configures the cellular structure of the intestinal mucosa ( Sutterwala and Flavell, 2009 ; Ruiz et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

Potential Immunomodulatory Activity of a Selected Strain Bifidobacterium bifidum H3-R2 as Evidenced in vitro and in Immunosuppressed Mice

et al. 2020

View full text Add to dashboard Cite

The microbiota is directly involved in the development and modulation of the intestinal immune system. In particular, members of the genus Bifidobacterium play a primary role in immune regulation. In the present study, Bifidobacterium bifidum H3-R2 was screened from 15 bifidobacterium strains by in vitro experiment, showing a positive tolerance to digestive tract conditions, adhesion ability to intestinal epithelial cells and a regulatory effect on immune cell activity. Immunostimulatory activity of B. bifidum H3-R2 was also elucidated in vivo in cytoxan (CTX)-treated mice. The results showed that the administration of B. bifidum H3-R2 ameliorated the CTX-induced bodyweight loss and imbalanced expression of inflammatory cytokines, enhanced the production of secretory immunoglobulin A (SIgA), and promoted splenic lymphocyte proliferation, natural killer (NK) cell activity and phagocytosis of macrophages in immunosuppressed mice. In addition, B. bifidum H3-R2 restored injured intestinal mucosal, and increased the villus length and crypt depth in CTX-treated mice. The results could be helpful for understanding the functions of B. bifidum H3-R2, supporting its potential as a novel probiotic for immunoregulation.

show abstract

Beneficial effects of Bifidobacterium longum subsp. longum BB536 on human health: Modulation of gut microbiome as the principal action

Cited by 90 publications

References 91 publications

Oral Administration of Microencapsulated B. Longum BAA-999 and Lycopene Modulates IGF-1/IGF-1R/IGFBP3 Protein Expressions in a Colorectal Murine Model

Oral Administration of Microencapsulated B. Longum BAA-999 and Lycopene Modulates IGF-1/IGF-1R/IGFBP3 Protein Expressions in a Colorectal Murine Model

Gut microbiota modulation with long-chain corn bran arabinoxylan in adults with overweight and obesity is linked to an individualized temporal increase in fecal propionate

Potential Immunomodulatory Activity of a Selected Strain Bifidobacterium bifidum H3-R2 as Evidenced in vitro and in Immunosuppressed Mice

Contact Info

Product

Resources

About